Single Cell Landscape of HBV-related Acute-on-chronic Liver Failure Patients

Launched by QILU HOSPITAL OF SHANDONG UNIVERSITY · Mar 4, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring the immune system of patients suffering from HBV-related acute-on-chronic liver failure, which is a serious condition where the liver suddenly stops working properly. The researchers will look closely at the blood cells of these patients using a technique called single-cell RNA sequencing. This method helps to better understand how the immune system is affected in these patients, which could lead to new treatments or improvements in care.

To be eligible for this study, participants need to be between the ages of 65 and 74 and have acute liver failure caused specifically by the hepatitis B virus (HBV). They should not have any other types of liver disease, like those caused by alcohol or other viruses, and must not have severe health problems affecting other organs. Those who join the study will have their blood samples taken and analyzed, helping researchers learn more about this condition. Remember, this trial is currently looking for participants, so if you or someone you know fits the criteria, it could be a valuable opportunity to contribute to medical research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Acute liver failure is a well-defned medical emergency which is defned as a severe liver injury, leading to coagulation abnormality usually with an INR ≥ 1.5, and any degree of mental alteration (encephalopathy) in a patient without pre-existing liver disease and with an illness of up to 4 weeks duration
• Exclusion Criteria:
• • Associated with other types of hepatitis virus infection or HIV infection, alcoholic liver disease, autoimmune liver disease, drug-induced liver injury; ② Suffering from primary liver cancer or severe heart, digestive, lung, kidney, neurological and psychiatric diseases; ③ Patients with incomplete data and patients unable to participate in the experiment.